ארצות הברית - אנגלית - NLM (National Library of Medicine)

the medicines company - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 2 mg in 1 ml - 1.  prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.  efficacy of the 32 mg single dose beyond 24 hours in these patients has not been established. 2.  prevention of postoperative nausea and/or vomiting.  as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.  in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.  for patients who do not receive prophylactic ondansetron injection and experience nausea and/or vomiting postoperatively, ondansetron injection may be given to prevent further episodes (see   clinical trials ). the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of cons

ארצות הברית - אנגלית - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 8 mg - ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: - highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . - initial and repeat courses of moderately emetogenic cancer chemotherapy. - radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. ondansetron is contraindicated in patients: - known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see adverse reactions ( 6.2)] . - receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness. risk summary available data do not reliably inform the association of ondansetron and adverse fetal outcomes. published epidemiological studies on the association between ondansetron and fetal outcomes have reported incon

ארצות הברית - אנגלית - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomor

ארצות הברית - אנגלית - NLM (National Library of Medicine)

proficient rx lp - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 8 mg - the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. ondansetron tablets, usp are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

medsource pharmaceuticals - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m 2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets usp and ondansetron orally disintegrating tablets usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hyp

ארצות הברית - אנגלית - NLM (National Library of Medicine)

physicians total care, inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron hydrochloride 2 mg in 1 ml - - prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. efficacy of the 32 mg single dose beyond 24 hours in these patients has not been established. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron injection, usp is recommended even where the incidence of postoperative nausea and/or vomiting is low. for patients who do not receive prophylactic ondansetron injection, usp and experience nausea and/or vomiting postoperatively, ondansetron injection, usp may be given to prevent further episodes (see clinical trials). ondansetron injection, usp is contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondanse

ארצות הברית - אנגלית - NLM (National Library of Medicine)

rnabaxy pharmaceuticals inc. - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 4 mg - 1. prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m2 . 2. prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets, usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness whe

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 2.5 mg/ml (equivalent: ondansetron, qty 2 mg/ml) - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate dihydrate; water for injections - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 2.5 mg/ml (equivalent: ondansetron, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; sodium citrate dihydrate - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

stat rx usa llc - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets usp and ondansetron orally disintegrating tablets usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and los